Developing nanoparticle formulations of poorly soluble drugs

Pharmaceutical Technology Europe

Volumn 20, Issue 11, 2008, Pages 24-28

  Nekkanti, Vijaykumar ^a   Karatgi, Pradeep ^a   Joshi, Mahendra ^a   Pillai, Raviraj ^a  

^a DR REDDY'S LABORATORIES LTD   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CANDESARTAN HEXETIL; DRUG CARRIER; FENOFIBRATE; HYDROXYPROPYLMETHYLCELLULOSE; KETOCONAZOLE; NANOPARTICLE; SURFACTANT;

ARTICLE; DISPERSION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG QUALITY; DRUG RESEARCH; DRUG SOLUBILITY; DRUG SYNTHESIS; HARDNESS; PARTICLE SIZE; PHARMACEUTICAL CARE; SUSPENSION; TABLET DISINTEGRATION TIME; TABLET FORMULATION; VISCOSITY; X RAY DIFFRACTION;

EID: 56349146207     PISSN: 01646826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. C. Lipinski, Am. Pharmaceut. Rev., 5(Fall), 82-85 (2002).
2. C.A. Lipinski et al., Adv. Drug Delivery Rev., 46(1), 3-26 (2001).
3. J. Hecq et al., Int. J. Pharm., 299(1), 167-177 (2005).
4. H.B. Levine (ed.), Ketoconazole in the Management of Fungal Disease (Adis Press, New York, NY, USA,1982).
5. M. H. Davidson et al., Clinical Therapeutics, 27(6), 715-727 (2005).
6. H. Stenhoff et al., Journal of Chromatography B: Biomedical Sciences and Applications, 731(2), 411-417 (1999).
7. E.M. Liversidge, G.G. Liversidge and E.R. Cooper, Eur. J. Pharm. Sci., 18(2), 113-120 (2003).
8. G.G. Liversidge and K.C. Cundy, Int. J. Pharm., 125(1), 91-97 (1995).
9. S. Basa et al., Drug Dev. Ind. Phar., (2008) DOI: 10.1080/ 03639040802005024.